HHGC
BBIO icon

Hunting Hill Global Capital’s BridgeBio Pharma BBIO Stock Holding History

Hunting Hill Global Capital’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-10,387
Closed -$179K – 114
2023
Q2 		$179K Buy
+10,387
New +$156K 0.06% 86

Other funds holding BBIO

KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Hunting Hill Global Capital's BBIO Position: Q3 2023 in Review

Hunting Hill Global Capital sold out of BridgeBio Pharma (BBIO) in Q3 2023, closing a stake of 10,387 shares — an estimated $179K sold.

Hunting Hill Global Capital first reported a position in BBIO in Q2 2023 and held it in 1 quarter. The position peaked at $179K in Q2 2023. 221 funds tracked by Wall St. Rank hold BBIO as of Q3 2023.

  • Hunting Hill Global Capital reported no remaining BridgeBio Pharma position as of Q3 2023 after selling out during the quarter.
  • Hunting Hill Global Capital sold 10,387 BridgeBio Pharma shares in Q3 2023, an estimated $179K.
  • Hunting Hill Global Capital first reported a position in BridgeBio Pharma in Q2 2023 and held it in 1 quarter.
  • Hunting Hill Global Capital's BridgeBio Pharma position peaked at $179K in Q2 2023.
  • 221 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q3 2023.

Based on Hunting Hill Global Capital's 13F filing for Q3 2023, filed 14 Nov 2023.